


Molecular science and electronic health records: what does the future hold?


Dr Adam Butterworth HDRUK Cambridge 23<sup>rd</sup> June 2021



### The challenge and opportunity




Bridging the gap between genotype and phenotype by linking multiple layers of molecular and other data with e-health records




## **Understanding Causes of Disease:**from molecules to electronic health records





## **Understanding Causes of Disease:**from molecules to electronic health records






### Integrating genomes, health records & telomere length in 500,000 people




#### Observational associations with 123 diseases




Telomere length (standardised)

197 genetic signals for telomere length



#### Causal associations suggested for 31 diseases




MR = P < 0.05 = P < 4.1e-04

Observational  $\bigcirc$   $P \ge 0.05$   $\bigcirc$  P < 0.05  $\bigcirc$  P < 4.1e-04

### An atlas of ~2000 genotypeprotein associations









#### **HDRUK Multi-omics Cohorts Consortium**



#### 13 cohorts, >800K participants




### Integrative analyses of multi-omic, genomic and EHR data



- Multi-disease aetiology
- Therapeutic target prioritisation
- Risk prediction

## Testing ~1000 proteins for causal effects on >200 diseases and traits










# Genetic signals for ~100 proteins associated with SARS-CoV2 or COVID-19 response










## Integrating genomics, transcriptomics, proteomics and COVID-19 outcomes to identify potential treatments











## **Understanding Causes of Disease:**from molecules to electronic health records





### Publicly accessible community resources







- 65 billion associations
- ~20,000 users
   from 100 countries
- Millions of database queries
- Cited in 610 papers

### Polygenic risk scores



A weighted sum of many diseaseassociated genetic variants






## Polygenic risk scores improve prediction of coronary heart disease in UK Biobank



"Polygenic risk scores.....could translate into meaningful clinical benefit if applied at scale, and lead to the prevention of 7% more CVD events than conventional risk factors alone."


	Overall C-index (95%CI)			C-index changes (95% CI)
Conventional risk factors	0.724 (0.715, 0.732)	•		Reference
Plus polygenic risk scores	0.745 (0.737, 0.754)		-	0.022 (0.017, 0.026)
Plus C-reactive protein	0.729 (0.720, 0.737)	-		0.005 (0.003. 0.007)
		0.00 0.01	0.02	0.03
		C-index changes (95% CI) versus reference model		





# Combining PGS with proteomics to identify aetiological pathways










#### HDRUK Health Data Research UK

### **Polygenic Score Catalog**

An open database created in partnership with EMBL-EBI, NHGRI and ClinGen







All published polygenic scores, systematic benchmarking


### Meta data about each polygenic score





Score Construction				
PGS Name	metaGRS_CAD			
Variants				
Original Genome Build	hg19			
Number of Variants	1,745,179			
Development Method				
Name	metaGRS			
Parameters	metaGRS log(HR) mixing weights: GRS46K=0.1278, FDR202=0.2359 and 1000Genomes=0.2400			

Score Details



### **Guidelines for reporting PGS**



Reporting standards necessary for PGS reproducibility, translation and public trust

#### Perspective


### Improving reporting standards for polygenic scores in risk prediction studies

https://doi.org/10.1038/s41586-021-03243-6

Received: 20 April 2020

Accepted: 15 January 2021

Published online: 10 March 2021




Hannah Wand<sup>1,2,31</sup>, Samuel A. Lambert<sup>3,4,5,6,7,31</sup>, Cecelia Tamburro<sup>8</sup>, Michael A. Iacocca<sup>1</sup>,
Jack W. O'Sullivan<sup>1,2</sup>, Catherine Sillari<sup>8</sup>, Iftikhar J. Kullo<sup>9</sup>, Robb Rowley<sup>8</sup>, Jacqueline S. Dron<sup>10,11</sup>,
Deanna Brockman<sup>10</sup>, Eric Venner<sup>12</sup>, Mark I. McCarthy<sup>13,14</sup>, Antonis C. Antoniou<sup>15</sup>,
Douglas F. Easton<sup>15</sup>, Robert A. Hegele<sup>11</sup>, Amit V. Khera<sup>10</sup>, Nilanjan Chatterjee<sup>16,17</sup>,
Charles Kooperberg<sup>18</sup>, Karen Edwards<sup>19</sup>, Katherine Vlessis<sup>20</sup>, Kim Kinnear<sup>20</sup>,
John N. Danesh<sup>5,6,21</sup>, Helen Parkinson<sup>6,7</sup>, Erin M. Ramos<sup>8</sup>, Megan C. Roberts<sup>22</sup>,
Kelly E. Ormond<sup>20,23</sup>, Muin J. Khoury<sup>24</sup>, A. Cecile J. W. Janssens<sup>25</sup>, Katrina A. B. Goddard<sup>26,27</sup>,
Peter Kraft<sup>28</sup>, Jaqueline A. L. MacArthur<sup>7</sup>, Michael Inouye<sup>3,4,5,6,21,29,32</sup> &
Genevieve L. Wojcik<sup>30,32</sup> 

Genevieve L. Wojcik<sup>30,32</sup>

Polygenic risk scores (PRSs), which often aggregate results from genome-wide association studies, can bridge the gap between initial discovery efforts and clinical applications for the estimation of disease risk using genetics. However, there is notable heterogeneity in the application and reporting of these risk scores, which hinders the translation of PRSs into clinical care. Here, in a collaboration between the Clinical Genome Resource (ClinGen) Complex Disease Working Group and the


## **Understanding Causes of Disease:**from molecules to electronic health records





## Linking genomes and longitudinal EHRs to identify causes of extreme mutation rates





4 with likely genetic explanations



5 with paternal cancer and chemotherapy prior to conception



#### The future



### 1. Enhanced diversity



**BELIEVE study** 



**Kadoorie Biobank** 



**Mexico City Prospective Study** 



**Million Veteran Program** 

#### The future



1. Enhanced diversity

2. Deeper data linkages



Led by Health Data Research UK


#### The future



1. Enhanced diversity

2. Deeper data linkages

3. Multimorbidity















































### Acknowledgements



Understanding Causes of Disease theme members

**Multi-omics Cohorts Consortium** 

Polygenic Score Catalog team

HDR UK Cambridge Hub team and Executive committee

Patient and public panels, representatives and Steering Committee members

Study participants

HDRUK team